1 sent a descendant of an ancestral prototypic CDKN2 gene.

2 cyclin-dependent kinase inhibitor p16 (MTS1, CDKN2) gene.

3  p53, PTEN, K-ras, EGFR, MTAP, and p16 (MTS1/CDKN2) genes.

4                                      The p16/CDKN2 gene, a cyclin dependent kinase inhibitor, is a we

5  D54 MG, that did not express endogenous p16/CDKN2 gene and were easily infected with adenovirus vect

6 uence similarity to members of the mammalian CDKN2 gene family, which includes the tumor suppressor l

7 ized the RNA expression properties of a fish CDKN2 gene from Xiphophorus helleri and X. maculatus.

8 though the frequency of mutations in the p16/CDKN2 gene has been detected in approximately 30% of non

9  AML1-TEL fusion proteins as well as TEL and CDKN2 gene inactivation in leukemia transformation and p

10 mozygous deletions are the main cause of p16/CDKN2 gene inactivation.

11               The penetrance of these mutant CDKN2 genes is not yet established, nor is the risk of n

12                                The p16 (MTS1/CDKN2) gene localized at the 9p21 chromosomal region enc

13 pG island encompassing the 5' end of the p16/CDKN2 gene may be a mechanism of transcriptional silenci

14 s study we investigated whether aberrant p16/CDKN2 gene methylation correlated with absence of p16 ex

15                                          The CDKN2 gene on chromosome 9p21 that encodes the p16 inhib

16 utations and homozygous deletions of the p16/CDKN2 gene, respectively.

17 f the CpG island in the 5' region of the p16/CDKN2 gene showed that exon 1 was extensively methylated

18 as lacking p16 expression exhibit intact p16/CDKN2 gene, suggesting that p16/CDKN2 is down-regulated

19 ient adenovirus carrying the cDNA of the p16/CDKN2 gene to infect and express high levels of p16 prot